185 completed, 50 unknown, 36 terminated, 26 recruiting. 330 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 330 | Completed 185, Unknown 50, Terminated 36, Recruiting 26, Not yet recruiting 12, Withdrawn 12, Active not recruiting 6, Enrolling by invitation 3 |
Follow Embolism and Thrombosis: new trials by email Literature Review of Embolism and Thrombosis trials Research Report on Embolism and Thrombosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications Freeze-Dried Plasma, Conventional Plasma - Thromboembolic Event, FDP | Phase 4 | Not yet recruiting | Teleflex | 867 | 2027-10-01 | 2026-09-30 |
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Iopidine to Decrease Intraocular Pressure Rise After Injections Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Retina Consultants of Delmarva | 120 | 2026-10-01 | 2026-10-23 |
| Investigating a Personalized Approach to Anti-Platelet Therapy Genotyping guided therapy for anti-platelet management - High Risk Bleeding | Phase 4 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 1760 | 2026-10-01 | 2026-09-08 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump Warfarin (INR 2-3) with placebo, Warfarin (INR 2-3) with aspirin - LVAD (Left Ventricular Assist Device) Thrombosis, LVAD | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 370 | 2026-06-25 | 2026-06-12 |
| Statins to Prevent Cancer Associated Blood Clots Rosuvastatin, Placebo Drug - Venous Thromboembolism, Cancer | Phase 4 | Recruiting | Brigham and Women's Hospital | 4000 | 2026-06-11 | 2026-09-16 |
| Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia Iheezo, Lidocaine pledget - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | Retina Consultants of Delmarva | 50 | 2026-05-20 | 2026-08-21 |
| A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens Enhanced dermatologic management, Enhanced IRR Prophylaxis, Enhanced VTE Prophylaxis (Cohort 1 only) - NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism) | Phase 4 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 122 | 2026-04-30 | 2026-03-13 |
| Second Line Endovascular Treatment in Acute DVT Thrombolysis/Thrombectomy - Deep Venous Thrombosis | Phase 4 | Not yet recruiting | Rush University Medical Center | 100 | 2026-04-01 | 2026-01-28 |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5% - Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) | Phase 4 | Enrolling by invitation | Harrow Inc | 236 | 2026-03-31 | 2026-04-07 |
| Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery fresh frozen plasma, prothrombin complex concentrate - Cardiac Valve Disease | Phase 4 | Recruiting | Konkuk University Medical Center | 100 | 2026-03-27 | 2026-06-17 |
| Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis batroxobin, Anticoagulation Agents - Cerebral Venous Thrombosis | Phase 4 | Recruiting | Xuanwu Hospital, Beijing | 72 | 2026-01-30 | 2026-01-20 |
| Open Label Treprostinil Raynaud's Study Oral treprostinil (UT-15C) sustained release tablets - Raynaud's Disease, Raynaud Phenomena | Phase 4 | Recruiting | Brigham and Women's Hospital | 30 | 2025-10-15 | 2026-03-24 |
| Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention rivaroxaban (10mg), Enoxaparin 40 mg SC - Deep Venous Thromboses, Laparotomy Patients | Phase 4 | Recruiting | Mayo Hospital Lahore | 212 | 2025-10-10 | 2025-11-21 |
| Apixaban or Enoxaparin After Head and Neck Cancer Surgery Enoxaparin, Apixaban - Venous Thromboembolism, Head and Neck Cancer | Phase 4 | Recruiting | Kiranya Arnold | 76 | 2025-10-01 | 2025-10-08 |
| Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients Warfarin (low-intensity anticoagulation), Warfarin (standard anticoagulation) - Advanced Heart Failure, Left Ventricular Assist Devices | Phase 4 | Not yet recruiting | Asan Medical Center | 94 | 2025-10-01 | 2025-07-23 |
| Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Anti-VEGF drug, Mecobalamin 5 MG, Placebo - Retinal Vein Occlusion (RVO) | Phase 4 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2025-08-01 | 2026-02-27 |
| STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel - Mitral Regurgitation | Phase 4 | Recruiting | Chinese Academy of Medical Sciences, Fuwai Hospital | 1032 | 2025-07-31 | 2026-03-09 |
Showing 20 of 330. Sign in to see all of them.
Thrombosis (107) · Venous Thrombosis (78) · Pulmonary Embolism (69) · Venous Thromboembolism (69) · Thromboembolism (39) · Retinal Vein Occlusion (35) · Hemorrhage (32) · Macular Edema (17) · Stroke (17) · Atrial Fibrillation (16) · Myocardial Infarction (15) · Coronary Artery Disease (14) · Cardiovascular Diseases (12) · Embolism (10) · Inflammation (9)
Vascular Diseases (323) · Cardiovascular Diseases (318) · Thrombosis (115) · Pathological Conditions, Signs and Symptoms (95) · Pathologic Processes (88) · Respiratory Tract Diseases (77) · Lung Diseases (75) · Thromboembolism (71) · Embolism (68) · Heart Diseases (54) · Venous Thrombosis (39) · Eye Diseases (34) · Nervous System Diseases (34) · Retinal Diseases (34)
Enoxaparin (35) · Rivaroxaban (32) · Aspirin (28) · apixaban (24) · Warfarin (20) · Clopidogrel (14) · Heparin, Low-Molecular-Weight (14) · Heparin (13) · Dalteparin (12) · Tinzaparin (12) · Ranibizumab (11) · Ticagrelor (11) · Tissue Plasminogen Activator (11) · Tranexamic Acid (9) · Nadroparin (8)
Assistance Publique - Hôpitaux de Paris (5) · Beijing Chao Yang Hospital (5) · Medical University of Vienna (5) · Azienda Ospedaliera Universitaria Policlinico (4) · Boston Scientific Corporation (4) · Novartis Pharmaceuticals (4) · Allergan (3) · Brigham and Women's Hospital (3) · Columbia University (3) · Helsinki University Central Hospital (3) · Johns Hopkins University (3) · Les Laboratoires des Médicaments Stériles (3) · Oregon Health and Science University (3) · Ottawa Hospital Research Institute (3) · Pirogov Russian National Research Medical University (3)
United States (94) · Canada (32) · China (30) · France (25) · Germany (19) · Italy (17) · Netherlands (16) · Spain (16) · Austria (15) · Denmark (14) · Switzerland (13) · South Korea (12) · United Kingdom (12) · Australia (10) · Belgium (10)
Sergio Siragusa, MD (4) · Juan J Badimon, PhD (3) · David Antoniucci, MD (2) · Dou-Sheng Bai, MD (2) · Eduardo Ramacciotti, MD, Ph.D. (2) · Guo-Qing Jiang, MS (2) · Kirill Lobastov, PhD (2) · Lana Castellucci, MD, FRCPC (2) · Ping Chen, MD (2) · Rajeev Muni (2)
PMID 35244208, PMID 24251360, PMID 28063245, PMID 33502773, PMID 41616808, PMID 10453824, PMID 10546719, PMID 11028492, PMID 11297486, PMID 11926893, PMID 12217281, PMID 12387283, PMID 12709915, PMID 12763484, PMID 12825542, PMID 12941734, PMID 12967792, PMID 15383488, PMID 15842354, PMID 16287790, PMID 17065639, PMID 17188044, PMID 17289685, PMID 17675159, PMID 18173426, PMID 18248600, PMID 18497320, PMID 1850220, PMID 18572147, PMID 18656008, PMID 18815396, PMID 18827132, PMID 19017588, PMID 1922252, PMID 19224134, PMID 19365036, PMID 19592101, PMID 19741062, PMID 19853892, PMID 20040086, PMID 20110127, PMID 20185783, PMID 20352167, PMID 20353588, PMID 20488410, PMID 20553388, PMID 20621900, PMID 20665856, PMID 20667989, PMID 20723861
2009 (4), 2014 (2), 2016 (2), 2018 (2), 2023 (2), 2008 (1), 2017 (1), 2019 (1), K23HL105897 (1), K23HL151871 (1), R34HL159119 (1), UG3HL176627 (1)